HomeApproved Treatments

NICE Final Guidance for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy Is Positive for Santhera

NICE Final Guidance for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy Is Positive for Santhera
Approved Treatments

Santhera Obtains Favorable NICE Final Guidance for AGAMREE (Vamorolone) as a Therapeutic Option for Duchenne Muscular Dystrophy.

AGAMREE (vamorolone) has been recommended for use in the National Health Service (NHS) in England, Wales, and Northern Ireland for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 and up by the National Institute for Health and Care Excellence (NICE), according to Santhera Pharmaceuticals.

Learn More: What is Agamree (vamorolone)? What is Agamree Used For?

SourceSanthera
Previous article
Dr. Liubov Gushchina’s Exon 17 Skipping Study Rewarded with Grant
Next article
Solid Biosciences Releases Information on Clinical Trial for SGT-003 Gene Therapy

LEAVE A REPLY

Please enter your comment!
Please enter your name here


Hot Topics

Load more

Related Articles

Load more

About us

We do not want children to die from a disease that can be cured. We want to give hope to families and ensure that all children with DMD are treated and regain their health.

Latest Articles

Cumberland Pharmaceuticals Announces Fantastic Results from Phase 2 FIGHT Duchenne Trial in DMD Heart Disease

Research 0
Cumberland Pharmaceuticals, a specialty pharmaceutical company with development efforts...

Entrada Therapeutics Receives UK Authorization to Begin ELEVATE-44-201

Research 0
ELEVATE-44-201, a Phase 1/2 multiple ascending dose (MAD) clinical...

Brazilian Children Over 7 and Their Families Demand Elevidys Gene Therapy from Anvisa

DMD 2
ELEVIDYS, the only currently approved gene therapy for DMD,...

Most Popular

Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy

DMD 1
A genetic condition known as Duchenne muscular dystrophy (DMD)...

Cures of Duchenne (List of All Researches)

Research 7
Dystrophin Gene Therapy MechanismCompanyDrugStatus Micro-dystrophin Gene Replacement Sarepta TherapeuticsElevidys/SRP-9001ApprovedMicro-dystrophin Gene ReplacementPfizerPF-06939926DiscontinuedMicro-dystrophin Gene...

Capricor Therapeutics Submits Application for Treatment of DMD Cardiomyopathy

Research 0
Capricor Therapeutics, a biotechnology company developing transformative cell and...

© 2024 DMD Warrior. All rights reserved.